Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XGN - Exagen Inc


IEX Last Trade
2.96
-0.030   -1.014%

Share volume: 19,413
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.99
-0.03
-1.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 18%
Dept financing 14%
Liquidity 73%
Performance 16%
Company vs Stock growth
vs
Performance
5 Days
-4.49%
1 Month
49.75%
3 Months
55.21%
6 Months
58.51%
1 Year
14.62%
2 Year
-35.22%
Key data
Stock price
$2.96
P/E Ratio 
-2.99
DAY RANGE
N/A - N/A
EPS 
-$0.97
52 WEEK RANGE
$1.30 - $3.71
52 WEEK CHANGE
$0.17
MARKET CAP 
51.811 M
YIELD 
N/A
SHARES OUTSTANDING 
17.386 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,823
AVERAGE 30 VOLUME 
$106,535
Company detail
CEO: Fortunato Rocca
Region: US
Website: http://www.exagen.com
Employees: 231
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Recent news